Hasil Pencarian - Ozgur Ozyilkan

  • Menampilkan 1 - 11 hasil dari 11
Perbaiki Hasil
  1. 1
    Scleroderma after 5-fluorouracil and folinic acid therapy in a patient with colon carcinoma

    Scleroderma after 5-fluorouracil and folinic acid therapy in a patient with colon carcinoma oleh Didem Arslan TAŞ, Ahmet Eftal YÜCE, Özgür ÖZYILKAN

    Diterbitkan 2014-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    5-Florourasil ve folinik asit tedavisi alan kolon karsinomlu olguda tedavi sonrasi skleroderma

    5-Florourasil ve folinik asit tedavisi alan kolon karsinomlu olguda tedavi sonrasi skleroderma oleh Didem Arslan Tas, Ahmet Eftal Yuce, Ozgur Ozyilkan

    Diterbitkan 2014-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Atypical sweet syndrome in the hands of small cell lung cancer patient associated with granulocyte colony-stimulating factor administration

    Atypical sweet syndrome in the hands of small cell lung cancer patient associated with granulocyte colony-stimulating factor administration oleh Dogan Ozlem, Ali Murat Sedef, Fatih Kose, Ozgur Ozyilkan

    Diterbitkan 2018-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Febrile neutropenia due to H1N1 infection: Rare entity

    Febrile neutropenia due to H1N1 infection: Rare entity oleh Ayberk A. Besen, Fatih Kose, Huseyin Mertsoylu, Umut Disel, Ozgur Ozyılkan

    Diterbitkan 2016-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Pertuzumab-mediated Cardiotoxicity: A Single Center Study.

    Pertuzumab-mediated Cardiotoxicity: A Single Center Study. oleh Özgür Özyilkan, Haldun Müderrisoğlu, Şenol Demırcan, Ahmet Sezer, Ahmet Sümbül, Ayşenur Uçar, Aynur Acıbuca

    Diterbitkan 2023-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Cardiotoxicity of trastuzumab emtansine (T-DM1): a single-center experience

    Cardiotoxicity of trastuzumab emtansine (T-DM1): a single-center experience oleh Aynur Acibuca, Ahmet Sezer, Mustafa Yilmaz, Ahmet Taner Sumbul, Senol Demircan, Ibrahim Haldun Muderrisoglu, Ozgur Ozyilkan

    Diterbitkan 2021-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Unexpected skin lesions after axitinib treatment

    Unexpected skin lesions after axitinib treatment oleh Ali Murat Sedef, Fatih Köse, Elvan Endoğru Rişvanoğlu, Ahmet Taner Sumbul, Melda Ulaş, Nebil Bal, Özgür Özyılkan

    Diterbitkan 2017-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Prognostic and predictive role of FOXP3 positive tumor infiltrating lymphocytes (TILs) in curatively resected non small cell lung cancer other than stage IA

    Prognostic and predictive role of FOXP3 positive tumor infiltrating lymphocytes (TILs) in curatively resected non small cell lung cancer other than stage IA oleh Fatih Kose, Tuba Canbolat, Alper Fındıkcıoglu, Ali Murat Sedef, Yurday Ozdemir, Ayberk Besen, Huseyin Mertsoylu, Ozgur Ozyilkan, Huseyin Abali

    Diterbitkan 2017-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Nöroendokrin tümörlerin klinikohistopatolojik özellikleri ve tedavi sonuçları: tek merkez deneyimi

    Nöroendokrin tümörlerin klinikohistopatolojik özellikleri ve tedavi sonuçları: tek merkez deneyimi oleh Ali Murat SEDEF, Fatih KÖSE, Ahmet Taner SÜMBÜL, Hüseyin MERTSOYLU, Ali Ayberk BESEN, Ahmet SEZER, Özgür ÖZYILKAN, Hüseyin ABALI

    Diterbitkan 2018-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer

    heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab f... oleh Sherko Kuemmel, Catherine Harper-Wynne, Yeon Hee Park, Fábio Franke, Michelino de Laurentiis, Eva Schumacher-Wulf, Daniel Eiger, Sarah Heeson, Andrés Cardona, Özgür Özyilkan, Flavia Morales-Vàsquez, Ciara Metcalfe, Marc Hafner, Eleonora Restuccia, Joyce O’Shaughnessy

    Diterbitkan 2024-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomized, double‐blind, phase III study

    Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomize... oleh Likun Chen, Jose David Gomez Rangel, Timucin Cil, Xingya Li, Irfan Cicin, Yihong Shen, Zhihua Liu, Ozgur Ozyilkan, Bondarenko Igor, Jun Chen, Kostiuk Oleksandr, Zhendong Chen, Helong Zhang, Ziyi Fu, Qingfeng Dong, Shuqiang Song, Jin‐Chen Yu, Li Zhang

    Diterbitkan 2023-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: